Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: riluzole Clear all
Completed Phase 2 Interventional Results available

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02238626
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (for MN-166), MN-166, riluzole
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 3 Interventional

Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)

NCT01257828
View directory record Official record
Conditions
Cervical Spondylotic Myelopathy
Interventions
riluzole, Placebo medication
Drug
Lead sponsor
AOSpine North America Research Network
Network
Eligibility
18 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 19, 2026, 1:16 PM EDT
Terminated Phase 4 Interventional

Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes

NCT00283309
View directory record Official record
Conditions
Mood, Memory Deficit
Interventions
Memantine, Riluzole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 19, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional Results available

Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder

NCT00805493
View directory record Official record
Conditions
Bipolar Disorder, Anxiety Disorders, Bipolar Affective Disorder, Bipolar Depression
Interventions
Riluzole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
9 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 19, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

NCT07447050
View directory record Official record
Conditions
Breast Cancer, Sarcoma, Gastric (Stomach) Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer
Interventions
Riluzole, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 19, 2026, 1:16 PM EDT
Active, not recruiting No phase listed Observational

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

NCT06529146
View directory record Official record
Conditions
Spinocerebellar Ataxias
Interventions
BHV-4157
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01378676
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 19, 2026, 1:16 PM EDT
Terminated No phase listed Observational

A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder

NCT01019967
View directory record Official record
Conditions
Childhood Obsessive-Compulsive Disorder, Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 19, 2026, 1:16 PM EDT
Completed No phase listed Observational

Safety of Riluzole in Patients With Acute Spinal Cord Injury

NCT00876889
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Riluzole
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Miami, Florida • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 2 Interventional

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01486849
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK-2017357, Placebo, Riluzole 50 MG
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Fresno, California • La Jolla, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00866840
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
riluzole
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders

NCT02081027
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Riluzole, placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 25 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

NCT01018056
View directory record Official record
Conditions
Tourette Syndrome
Interventions
D-serine, Riluzole, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003
View directory record Official record
Conditions
Major Depression
Interventions
Lamotrigine, Ketamine, Riluzole
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 19, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring

NCT05292209
View directory record Official record
Conditions
Atrial Fibrillation Paroxysmal
Interventions
Riluzole 50 MG
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 19, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Not applicable Interventional

Treatment of Refractory Schizophrenia With Riluzole

NCT00375050
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 19, 2026, 1:16 PM EDT
Terminated Phase 1 Interventional

Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT01018836
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
riluzole, whole-brain radiation therapy
Drug · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

Riluzole in Fragile X Syndrome

NCT00895752
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Riluzole
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)

NCT02019940
View directory record Official record
Conditions
PTSD
Interventions
Riluzole
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Riluzole in Mild Alzheimer's Disease

NCT01703117
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 19, 2026, 1:16 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Masitinib (6.0), Riluzole, Placebo, Masitinib (4.5)
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 81 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation

NCT02796755
View directory record Official record
Conditions
Inflammation, Fatigue
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 19, 2026, 1:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)

NCT02155829
View directory record Official record
Conditions
PTSD
Interventions
Riluzole, Placebo (for Riluzole)
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 19, 2026, 1:16 PM EDT